Generic Absorica LD Availability
Last updated on Apr 10, 2025.
See also: Generic Absorica
Absorica LD is a brand name of isotretinoin, approved by the FDA in the following formulation(s):
ABSORICA LD (isotretinoin - capsule;oral)
-
Manufacturer: SUN PHARM
Approval date: November 5, 2019
Strength(s): 8MG [RLD], 16MG [RLD], 20MG (discontinued) [RLD], 24MG [RLD], 28MG (discontinued) [RLD], 32MG [RLD]
Is there a generic version of Absorica LD available?
No. There is currently no therapeutically equivalent version of Absorica LD available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Absorica LD. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Oral pharmaceutical composition of isotretinoin
Patent 9,700,535
Issued: July 11, 2017
Inventor(s): Rao Rajesh & Fanda Anuj Kumar & Jain Satish Kumar & Singh Romi Barat
Assignee(s): SUN PHARMACEUTICAL INDUSTRIES LIMITEDAn oral pharmaceutical composition of isotretinoin with reduced food effect. A process for preparing the oral pharmaceutical composition of the present invention.
Patent expiration dates:
- August 4, 2035✓
- August 4, 2035
-
Low dose oral pharmaceutical composition of isotretinoin
Patent 9,750,711
Issued: September 5, 2017
Inventor(s): Madan Harish Kumar & Venkateshwaran Rathinasabapathy & Madan Sumit & Kochhar Ravi
Assignee(s): Sun Pharmaceutical Industries LimitedThe present invention provides a low dose oral pharmaceutical composition of isotretinoin having reduced food effect, in particular no food effect. The present invention further relates to a process for preparing the oral pharmaceutical composition of the present invention.
Patent expiration dates:
- May 29, 2035✓
- May 29, 2035
More about Absorica LD (isotretinoin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous uncategorized agents
- Breastfeeding
- En español
Patient resources
Other brands
Accutane, Claravis, Zenatane, Amnesteem, ... +3 more
Professional resources
Other brands
Accutane, Claravis, Zenatane, Amnesteem, ... +2 more
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
